Unavailable
Unavailable
Save time and jump to the most important pieces.
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
KUALA LUMPUR, Malaysia, April 15, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC) ("BioNexus" or the "Company"), a diversified biotechnology and specialty materials group headquartered in Malaysia and incorporated in Wyoming, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with the U.S. Securities and Exchange Commission. The Company's 2024 report showcases a year of strategic realignment, technological advancement, and enhanced corporate governance - positioning BGLC for sustainable long-term growth. Financial Resilience and Market Stability BGLC ended 2024 with a strong cash position of over $4million and total l
KUALA LUMPUR, Malaysia, March 08, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a technology company dedicated to innovation in the digital and healthcare space, has announced a strategic partnership with ML Tech to optimize the BGLC's Ethereum-based growth strategies. ML Tech is an AI-driven wealth management platform for digital assets regulated by the National Futures Association (NFA), and is headquartered in Miami, Florida. This collaboration follows the announced Ethereum treasury strategy by BGLC, marking its commitment to technological and financial innovation. Through this partnership, BGLC plans to leverage ML Tech's cutting-edge digital asset trading infrastru
SC 13G - BioNexus Gene Lab Corp (0001737523) (Subject)
8-K - BioNexus Gene Lab Corp (0001737523) (Filer)
10-K/A - BioNexus Gene Lab Corp (0001737523) (Filer)
10-K - BioNexus Gene Lab Corp (0001737523) (Filer)
KUALA LUMPUR, Malaysia, April 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (NASDAQ:BGLC), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. This important milestone reaffirms the Company's standing as a compliant and growth-focused public company. It marks the successful conclusion of a focused compliance initiative and paves the way for the Company to pursue its bold innovation roadmap, capit
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)
3 - BioNexus Gene Lab Corp (0001737523) (Issuer)